The largest opportunities for organ regeneration lie in diseases/disorders of the bone marrow, kidneys, liver, pancreas, and small intestine. Market segments covered by this report include bioartificial kidneys and livers/liver regeneration products, bone marrow regeneration products, pancreas regeneration products, and small intestine replacement products. Various tissue engineering technologies including genes, scaffolds, stem cells, and xenotransplants are being researched for applications in organ regeneration.
This new report also provides a clinical overview of selected diseases/disorders that are amenable to treatment with tissue-engineered and cell transplantation products and includes the most up-to-date incidence and prevalence figures.
This report is the fifth in a series of six Medtech Insight reports covering U.S. tissue engineering and cell transplantation markets. The final report in this series will provide an analysis of the U.S. market for tissue-engineered skin replacement and skin substitute products.
EXECUTIVE SUMMARY i. Clinical Applications for Organ Regeneration a. Bone Marrow Disease b. Diabetes c. Intestinal Disorders d. Kidney Disease e. Liver Disease ii. Tissue Engineering Technologies a. Biomaterials b. Cell Culture Technology c. Stem Cell Technology d. Immunoisolation Technology iii. Technologies Under Development for Organ Regeneration a. Bone Marrow Regeneration Technologies b. Intestine Regeneration Technologies c. Kidney Regeneration Technologies d. Liver Regeneration Technologies e. Pancreas Regeneration Technologies f. Bioartificial Organ Technologies iv. Market Analysis v. Methodology Exhibit ES-1: Organ Regeneration Products, Potential Market Forecast, 2009 and 2019 1. CLINICAL OVERVIEW OF TISSUE ENGINEERING APPLICATIONS FOR ORGAN REGENERATION 1.1 Disease Incidence 1.1.1 Bone Marrow Disease 126.96.36.199 Aplastic Anemia 188.8.131.52 Leukemia and Lymphoma 1.1.2 Diabetes 1.1.3 Intestinal Disorders 184.108.40.206 Intestinal Pseudo-Obstruction 220.127.116.11 Microvillus Inclusion Disease 18.104.22.168 Short Bowel Syndrome 1.1.4 Kidney Disease 1.1.5 Liver Disease 1.2 Existing Therapies 1.2.1 Ex Vivo Systems 22.214.171.124 Kidney Dialysis Systems 1.2.2 Organ Transplantation 126.96.36.199 Bone Marrow Transplantation 188.8.131.52 Kidney Transplantation 184.108.40.206 Liver Transplantation 220.127.116.11.1 Split Cadaveric Livers 18.104.22.168.2 Liver Segments from Living Donors 22.214.171.124 Pancreas Transplantation 126.96.36.199 Intestinal Transplantation Exhibit 1-1: Incidence and Prevalence of Major Organ Diseases/Disorders Exhibit 1-2: Organ Transplantation, by Type, Procedure Volumes, and Waiting List Exhibit 1-3: Average Estimated First-Year Billed Charges, Per Transplant 2. TISSUE ENGINEERING AND ORGAN REGENERATION TECHNOLOGIES 2.1 Biomaterials 2.1.1 Synthetic Biomaterials 2.1.2 Biologically Derived Biomaterials 188.8.131.52 Collagen 184.108.40.206 Xenogeneic Tissue 2.1.3 Hybrid Biomaterials 2.1.4 Genetically Engineered Biomaterials 220.127.116.11 Deoxyribonucleic Acid Transfection Vectors 18.104.22.168 Genetically Manipulated Cells 22.214.171.124 Three-Dimensional Polymer Technology 126.96.36.199 Transgenics 188.8.131.52 Fibroblasts 184.108.40.206 Immortalized Neural Stem Cells 220.127.116.11 Gene-Activated Matrices 2.1.5 Scaffolds 2.1.6 Vascular Grafts 2.2 Cell Culture Technology 2.2.1 Bioreactors 18.104.22.168 Flatbed Perfusion Systems 22.214.171.124 Hollow Fiber Bioreactor Systems 126.96.36.199 Cell Suspension Systems 188.8.131.52 Disposable Bioreactors 2.3 Stem Cell Technology 2.3.1 Cell Extraction and Expansion 2.3.2 Bioreactors 2.4 Immunoisolation Technology 2.4.1 Chimeric Immunity 2.4.2 Cell Encapsulation Technology Exhibit 2-1: 2010, Selected Synthetic Biomaterials Used in Tissue Engineering Exhibit 2-2: 2010, Selected Natural Biomaterials Used in Tissue Engineering Exhibit 2-3: 2010, Selected Current and Emerging Cell Extraction, Expansion, and Separation Products and Technologies 3. TISSUE ENGINEERING AND CELL TRANSPLANTATION: U.S. MARKETS FOR ORGAN REGENERATION PRODUCTS 3.1 Emerging Technologies and Products 3.1.1 Genes 3.1.2 Scaffolds 3.1.3 Stem Cells 3.1.4 Xenotransplants 3.1.5 Bone Marrow 184.108.40.206 Gamida Cell 220.127.116.11 Osiris Therapeutics 18.104.22.168 SituGen 22.214.171.124 University of Texas M.D. Anderson Cancer Center and the ViaCord Research Institute/ViaCord/PerkinElmer 3.1.6 Intestine 3.1.7 Kidney 126.96.36.199 Tengion 3.1.8 Liver 188.8.131.52 Cytonet 184.108.40.206 StemCells 220.127.116.11 Vesta Therapeutics 3.1.9 Pancreas 18.104.22.168 BioTime 22.214.171.124 Cerco Medical 126.96.36.199 Geron 188.8.131.52 Juvenile Diabetes Research Foundation 184.108.40.206 Osiris Therapeutics 220.127.116.11 ViaCyte 18.104.22.168 StemCells 22.214.171.124 TheraCyte 126.96.36.199 Transition Therapeutics 188.8.131.52 ViaCord/PerkinElmer 184.108.40.206 Vitro Biopharma/Vitro Diagnostics 3.2 Artificial Organ Technologies 3.2.1 Bioartificial Kidney 3.2.2 Bioartificial Liver 220.127.116.11 Excorp Medical 18.104.22.168 Gambro 22.214.171.124 HepaLife Technologies 126.96.36.199 Hep-Art Medical Devices 188.8.131.52 Hybrid Organ 184.108.40.206 Vital Therapies 220.127.116.11 Xenogenics/MultiCell Technologies 3.2.3 Artificial Pancreas 18.104.22.168 Juvenile Diabetes Research Foundation 22.214.171.124 Medtronic 3.3 Market Analysis 3.3.1 Market Drivers 3.3.2 Market Limiters 3.4 Competitors Exhibit 3-1: 2010, Selected Emerging Treatment Products for Liver Failure Exhibit 3-2: 2010, Selected Emerging Treatment Products for Pancreatic Failure Exhibit 3-3: 2010, Selected Bioartificial and Artificial Organ Products Exhibit 3-4: Medtronic's STAR 3 Study Results Exhibit 3-5: Organ Regeneration Products, Potential Market Forecast, 2009 and 2019 Exhibit 3-6: Organ Regeneration Technologies, by Indication, 2009 and 2019 4. COMPANY PROFILES 4.1 BioTime, Inc. 4.2 Cerco Medical LLC 4.3 Cytonet GmbH & Co. KG 4.4 Geron Corporation 4.5 Osiris Therapeutics, Inc. 4.6 PerkinElmer, Inc. 4.7 StemCells, Inc. 4.8 Tengion, Inc. 4.9 Vesta Therapeutics, Inc. 4.10 ViaCyte, Inc. APPENDIX: COMPANY LISTING